Clinical Scorecard: Quality of Life Outcomes After Salvage Radical Prostatectomy in Patients with Recurrent Prostate Cancer Post-Radiotherapy or Focal Treatment

At a Glance

Key Highlights

• Salvage radical prostatectomy provides up to 95% 5-year cancer-specific survival regardless of primary treatment modality.
• Urinary continence rates after sRP have improved in recent studies, reaching up to 90%, especially after focal therapy.
• Long-term health-related quality of life (HRQOL) outcomes after sRP do not significantly differ between patients with prior radiotherapy or focal therapy.

Guideline-Based Recommendations

Diagnosis

• Identify local prostate cancer recurrence after primary non-surgical treatment via clinical and biochemical assessment.
• Use biochemical recurrence definition as two consecutive PSA values ≥ 0.2 ng/ml post-sRP.

Management

• Consider salvage radical prostatectomy for local recurrence after radiotherapy or focal therapy.
• Perform nerve-sparing intraoperatively when feasible to optimize functional outcomes.
• Use open surgical approaches predominantly for salvage treatment.

Monitoring & Follow-up

• Assess urinary continence using International Consultation of Urinary Incontinence questionnaire (ICIQ-SF) and pad usage.
• Evaluate erectile function with simplified International Index of Erectile Function (IIEF-5).
• Monitor HRQOL using EORTC QLQ-C30 and prostate-specific QLQ-PR25 questionnaires preoperatively and during follow-up.
• Follow-up at 3 months post-surgery and annually thereafter.

Risks

• High complication rates and potential for urinary incontinence post-sRP, though recent data show improved continence.
• Functional outcomes may vary depending on primary treatment modality, with better continence after focal therapy.

Patient & Prescribing Data

Patients undergoing salvage radical prostatectomy after radiotherapy or focal therapy for recurrent prostate cancer.

Salvage radical prostatectomy yields comparable long-term HRQOL outcomes regardless of prior primary treatment modality, with improved functional results reported in recent cohorts.

Clinical Best Practices

• Use validated questionnaires (EORTC QLQ-C30, QLQ-PR25, ICIQ-SF, IIEF-5) to assess patient-reported outcomes pre- and post-sRP.
• Stratify patients by primary treatment modality to inform prognosis and counseling.
• Consider patient perspectives and HRQOL data in clinical decision-making for salvage treatment.
• Apply multivariable analyses to identify predictors of good HRQOL and functional recovery.
• Maintain rigorous follow-up with biochemical and functional assessments to monitor treatment success and quality of life.

References

• Cancer-specific survival rates after salvage radical prostatectomy
• Functional outcomes and continence rates after salvage radical prostatectomy
• Patient-reported outcome measures and quality of life assessment tools
• Guidelines on biochemical recurrence definition post-radical prostatectomy